UNSPSC 51313505: Dorastine

This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3087NKH40A. European Medicines Agency schedules Dorastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06370MIG. Dorastine generally arises in the molecular formula C20H22CLN3. The term DORASTINE is an International Non-Proprietary Name or INN. DORASTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule dorastine under HS 29333999 and SITC 51574. As of Q4 2014, DORASTINE remains the US FDA Preferred Term for this commodity. Dorastine bears US NLM identifiers UMLS ID C2699801 and NCI Concept Code C76061. SMILES: CLC1CC2C3C(N(C2CC1)CCC1CCC(NC1)C)CCN(C3)C.

UNSPSC 51313505 Dorastine is a Commodity code under which state and local governments procure pharmaceutical products, specifically naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter medications to support community health initiatives, pharmacy benefit programs, and emergency response capabilities. The recent solicitations show counties, state health departments, and multi-state cooperative purchasing alliances buying finished pharmaceutical products and related systems through competitive bidding processes, with delivery and distribution managed through authorized wholesalers or direct to end-use facilities. Work under this code spans both emergency-response pharmaceuticals (naloxone kits for overdose intervention) and routine pharmacy supplies (generic drugs and OTC products distributed through state and local health systems).

Issuing bodies include county health departments, state health and human services agencies, and cooperative purchasing organizations that aggregate demand across multiple jurisdictions. Seminole County, Florida recently issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products to serve participating state and local facilities across multiple states including Oregon, with proposals due March 26, 2026 and contract awards effective July 1, 2026; and the Texas Health and Human Services Commission issued an RFI in April 2026 exploring direct-to-manufacturer prescription programs. Geographic activity centers on Florida, Minnesota, Texas, and Oregon based on recent postings. Vendors responding to these solicitations must comply with cGMP and Drug Supply Chain Security Act requirements, maintain authorized wholesaler relationships where required, provide electronic data interchange capability, and carry comprehensive insurance including commercial general liability coverage of $2 million to $5 million depending on the opportunity.